Di Yi Cai Jing·2025-12-15 10:55Group 1 - The core point of the news is that Fosun Pharma will acquire a controlling stake in Green Valley Pharmaceutical for approximately 1.412 billion yuan, making it a subsidiary of Fosun Pharma [1] - Green Valley's main product, the sodium mannitol capsule (marketed as "Jiuyi"), is intended for the treatment of mild to moderate Alzheimer's disease and will be integrated into Fosun Pharma's innovative drug pipeline [1][3] - Alzheimer's disease is a significant public health challenge characterized by progressive memory impairment and cognitive decline, with a substantial unmet clinical need for effective treatments [1] Group 2 - The sodium mannitol capsule received conditional approval from the National Medical Products Administration in November 2019 but faced production suspension due to the expiration of its registration certificate in November 2024 [3] - Green Valley Pharmaceutical must complete ongoing post-marketing confirmatory clinical trials and obtain approval from the drug regulatory authority before resuming commercial production and sales of the sodium mannitol capsule [3] - Fosun Pharma's research team is actively conducting the necessary clinical trials to support the product's re-approval and plans to initiate international multi-center clinical trials to benefit more Alzheimer's patients [3][4] Group 3 - Fosun Pharma's CEO emphasized that this investment in Green Valley Pharmaceutical is a strategic move to strengthen its presence in the central nervous system treatment sector, particularly in addressing Alzheimer's disease as a key issue related to population aging [4]